Eli Lilly & Co. (LLY) to Charge $2,100 Per Dose of Bebtelovimab Antibody Drug - WSJ
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,183.46 +0.13%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: +41.0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: +41.0%
Join SI Premium – FREE
Lilly (NYSE: LLY) to Charge List Price of $2,100 Per Dose of Bebtelovimab Antibody Drug -- WSJ
- to Start Commercial Distribution of Covid-19 Antibody Treatment Week of Aug. 15
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Lilly's once-weekly basal insulin for type 2 diabetes
- Pool Corporation names former Constellium CEO to its board
- Bimegren Energy (BESS) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
